NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
13 trialsNCT03375320 2026-03-18
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04211337 2025-04-20
LIBRETTO-531
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT01908426 2021-05-06
CELESTIAL
Exelixis
Phase 3 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT01605227 2018-03-14
COMET-1
Exelixis
Phase 3 Completed